Ocular Therapeutix Inc. (OCUL)
Bid | 5.9 |
Market Cap | 1.25B |
Revenue (ttm) | 63.66M |
Net Income (ttm) | -193.51M |
EPS (ttm) | -1.22 |
PE Ratio (ttm) | -6.45 |
Forward PE | -6.63 |
Analyst | Buy |
Ask | 10 |
Volume | 610,579 |
Avg. Volume (20D) | 1,551,286 |
Open | 8.01 |
Previous Close | 8.80 |
Day's Range | 7.82 - 8.33 |
52-Week Range | 4.79 - 11.78 |
Beta | 1.49 |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammati...
Analyst Forecast
According to 10 analyst ratings, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 116.01% from the latest price.
Stock ForecastsEarnings Surprise
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

1 month ago · seekingalpha.com
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster PotentialOcular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has ...